secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGM Biosciences, Inc. (—)
CIK:        0001496323
Form:       8-K/A
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0000950170-25-034626
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

IGM Biosciences estimates restructuring charges of $0.7M-$2.0M from 2025 headcount reduction
--------------------------------------------------------------------------------

- Total restructuring charges estimated between $0.7M and $2.0M.
- Cash expenditures for severance and termination: $4.1M to $5.4M, offset by non-cash stock compensation credit of $3.4M.
- Substantially all charges expected to be recognized in Q1 2025.
- Follows Jan 10 announcement halting imvotamab and IGM-2644 development and reducing workforce by ~73%.
- Estimates subject to assumptions; actual costs may differ materially.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1496323/000095017025034626/0000950170-25-034626-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1496323/000095017025034626/igms-20250107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-034626

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer